Vivimed has agreed to pay $1.9 million to settle economic loss claims against consumers and insurers who purchased contaminated Losartan blood pressure medications. The settlement resolves claims related to Vivimed Losartan products that were found to contain probable human carcinogens—specifically NDMA, NDEA, and NMBA—in their active pharmaceutical ingredients. If you purchased Vivimed Losartan products at retail prices between January 1, 2016 and the present, you may be eligible to recover what you overpaid for these contaminated drugs.
This settlement addresses only economic losses—the difference between what consumers and insurers paid for contaminated medication versus what uncontaminated medication would have cost. It does not cover personal injury claims or medical monitoring costs, which remain separately litigated. The June 2, 2026 claim deadline means time is running short for eligible parties to file their claims and recover compensation.
Table of Contents
- What Contamination Was Found in Vivimed Losartan?
- Understanding the Health Risks and Why the Contamination Matters
- The Settlement Agreement and What It Covers
- How to File a Claim for Vivimed Losartan Compensation
- Key Limitations of the Economic Loss Settlement
- The Broader Sartan Drug Contamination Crisis
- What Consumers Should Know Going Forward
- Conclusion
What Contamination Was Found in Vivimed Losartan?
Vivimed Losartan contained three identified contaminants classified as probable human carcinogens: NDMA (N-nitrosodimethylamine), NDEA (N-nitrosodiethylamine), and NMBA (N-nitrosobis(2-methylpropyl)amine). These contaminants were not manufacturing errors or storage problems—they were present in the active pharmaceutical ingredients themselves, meaning the contamination originated at the raw material stage.
The presence of these substances in blood pressure medications raised serious health concerns since patients taking Losartan typically use it for chronic hypertension and would be exposed to these carcinogens regularly over extended periods. For context, NDMA in particular had been found in other sartan blood pressure drugs from different manufacturers between 2018 and 2020, prompting a broader FDA investigation into the supply chain. The discovery of similar contaminants in Vivimed’s formulation followed this same troubling pattern, suggesting systemic quality control failures across multiple suppliers of these critical medications.
Understanding the Health Risks and Why the Contamination Matters
Probable carcinogens like NDMA, NDEA, and NMBA are substances that may increase cancer risk with long-term exposure. Since Losartan is a medication typically prescribed for chronic blood pressure management—meaning patients take it daily for years or even decades—the exposure duration to these contaminants was potentially significant. However, the health risk assessment depends on the concentration of contaminants present, the duration of use, and individual factors like age and overall health.
The limitation of this settlement is important to understand: it only compensates economic loss (the price difference paid), not medical monitoring or personal injury claims. This means if you took contaminated Vivimed Losartan and later developed health problems, this settlement would not cover those medical expenses. Those claims are being pursued separately through ongoing litigation in the multidistrict litigation (MDL), which handles injury cases differently than economic loss settlements.
The Settlement Agreement and What It Covers
The Vivimed Losartan settlement is one component of a larger $15.26 million resolution addressing contaminated sartan blood pressure drugs from three manufacturers. Hetero Valsartan received the largest settlement amount at $11.37 million, followed by aurobindo Irbesartan at $2 million, and Vivimed Losartan at $1.9 million. The settlements cover retail purchases made between January 1, 2016 and the present, which captured the period when these contaminated products were being distributed to pharmacies and patients without their knowledge.
For example, if you purchased 90-day supplies of Vivimed Losartan from your local pharmacy between 2016 and 2026, each purchase represents a separate claim you can file. The settlement fund will be distributed based on the number of valid claims received, meaning if 10,000 people file claims, the $1.9 million will be divided accordingly. The amount you recover depends on how many eligible claims are filed and whether you can provide proof of purchase, such as pharmacy receipts or insurance records showing payment.
How to File a Claim for Vivimed Losartan Compensation
To claim compensation from the settlement, you must submit a claim by the June 2, 2026 deadline. Eligible claimants include individuals who purchased Vivimed Losartan at retail prices and entities that paid for such purchases, as well as insurers who covered costs. The settlement notice specifies that claims must be for retail purchases of the contaminated product during the January 1, 2016 to present period.
When filing your claim, you will need to provide documentation of your purchase, such as pharmacy receipts, prescription records, or insurance claim forms that show you paid for Vivimed Losartan. If you no longer have original receipts, your pharmacy or health insurance company can often provide proof of purchase. The claim process is administered by a settlement claims administrator, and detailed instructions for filing should be available through the MDL settlement website or via the settlement notice that was distributed.
Key Limitations of the Economic Loss Settlement
The most significant limitation of this settlement is that it covers only economic damages—essentially what consumers overpaid for contaminated medication—and does not address personal injury or medical monitoring claims. If you believe you suffered health problems from taking contaminated Vivimed Losartan, this settlement does not compensate you for medical treatment, hospital bills, or pain and suffering. Those claims remain in ongoing litigation and are evaluated separately through a different legal process.
Another important limitation: the settlement amount is fixed at $1.9 million regardless of how many valid claims are received. This means if 1,000 people claim $1,000 each, they would receive their full claim amount. But if 10,000 people claim $1,000 each, each claimant would receive a reduced pro-rata share (approximately $190 per person). The final amount you receive depends entirely on the number of eligible claims submitted, which you cannot predict in advance.
The Broader Sartan Drug Contamination Crisis
The Vivimed settlement is part of a much larger contamination problem in the blood pressure drug market that began surfacing in 2018. Major manufacturers including Valsartan, Irbesartan, Losartan, and other sartan-class drugs were recalled when the FDA discovered NDMA and related contaminants in products from multiple suppliers across different geographic sources. Between 2018 and 2020, dozens of recalls were issued, affecting millions of prescriptions in the United States and globally.
This broader crisis exposed weaknesses in pharmaceutical supply chain oversight and quality control standards. Many patients had to switch medications mid-treatment, some experienced blood pressure spikes during medication changes, and some discovered the contamination only after years of using the affected products. The multiple settlements now being resolved represent partial compensation for what was a significant public health failure affecting a common medication that millions of Americans depend on.
What Consumers Should Know Going Forward
If you took any blood pressure medication between 2016 and 2024, it is worth checking whether the specific product you used was subject to any FDA recalls or settlements. The FDA maintains a searchable database of recalls, and your pharmacy records or insurance statements can tell you exactly which manufacturer and generic version you received.
Even though the contaminated products have since been removed from distribution, understanding what you took in the past helps you file claims in any outstanding settlements. Moving forward, the lesson for consumers is to stay informed about recalls affecting your medications, keep pharmacy receipts for several years, and monitor FDA announcements about drug safety issues. While these settlements provide some compensation for economic losses, they underscore the importance of advocating for stronger pharmaceutical supply chain oversight and transparency about where medications are manufactured and sourced.
Conclusion
The $1.9 million Vivimed Losartan settlement resolves economic loss claims for consumers and insurers who purchased contaminated blood pressure medications containing probable human carcinogens. With a June 2, 2026 claim deadline, eligible individuals and entities who can provide proof of retail purchase should file claims to recover their overpayment for the defective product.
While the settlement does not cover personal injury claims—which remain in ongoing litigation—it provides compensation for the economic harm of purchasing contaminated medication at standard prices. If you purchased Vivimed Losartan between January 1, 2016 and the present, gather your pharmacy or insurance records and file your claim before the deadline expires. The $1.9 million pool will be divided among all valid claims submitted, making timely filing essential to securing your share of the compensation fund.
You Might Also Like
- Aurobindo Blood Pressure Drug Settlement Resolves NDMA Contamination Claims
- Capital Health Data Breach Settlement Resolves Claims Over Hospital Cyberattack
- Hetero Blood Pressure Drug Settlement Covers Purchasers of Certain Recalled Medications
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: